Clinical Trial Finder

Key

Inclusion Criteria:

1. Signed and dated informed consent form. 2. Diagnosis of HAE type I or

• II. 3.

For participants from Study C201, received at least one dose of study drug (including the non-attack visit) in Study C201. For participants from Study C306, participant was randomized (and for adolescent participants 12 to <18 years received a dose of study drug in a non-attack state at Visit 1) and completed Study C306, with 2 attacks treated, or after closure of that study by the Sponsor. 4. In the opinion of the Investigator, the participant (and parent/caregiver for adolescent participants) is willing and able to comply with the protocol. Key

Exclusion Criteria:

1. Pregnancy or breast-feeding. 2. Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study. 3. Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to enrollment in Part A. 4. For Part A: Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment. For Part B: If a participant is receiving long-term prophylactic therapy with one of the following medications indicated for HAE: plasma-derived C1-INH, danazol at less than or equal to 200 mg/day, anti-fibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study. 5. History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse. 6. Participation in any other investigational drug study within defined period. 7. Discontinued from parent study after enrollment for any study drug-related safety reason. 8. Use of concomitant medications that are potent CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, grapefruit) or potent CYP3A4 inducers (e.g., phenytoin, rifampicin, St. John's Wort).

Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained. Part B will include participants rolling over from Part A and additionally enroll participants from Study PHA022121-C201 who did not participate in Part A, and participants from Study PHA022121-C306 who elect to participate in this extension study and meet the eligibility requirements.

Arms

Experimental: Part B: Selected dose

Single dose of deucrictibant

Interventions

Drug: - deucrictibant selected dose

deucrictibant soft capsule for oral use